27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
619 Colombian API registrants were prescreened, 315 were assessed for eligibility, and 252 were enrolled (crenezumab-carrier, n=85; placebo-carrier, n=84; placebo-non-carrier, n=83; 160 [63%] women and 92 [37%] men) between Dec 20, 2013, and Feb 27, 2017. 237 (94%) completed the trial, with final data collection on March 22, 2022. 5 key findings →
Participants: 85 Evidence: high
Full summary, score breakdown and related studies → Original source
BackgroundZervimesine (CT1812) is a first-in-class, brain-penetrant sigma-2 receptor ligand that prevents binding and displaces Aβ42 oligomers from receptors on neuronal synapses. 3 key findings →
Design: clinical trial Participants: 153 Evidence: high
Full summary, score breakdown and related studies → Original source
Mean percentage change in plasma p-tau217 in the SAMe group was an increase of 53.22 (standard deviation [SD] 159.19) compared to 25.34 (SD 94.83) in the placebo group (standardized mean difference 37.58, 95% confidence interval -32.61, 107.76; p = 0.288). 4 key findings →
Design: clinical trial Participants: 63 Evidence: high
Full summary, score breakdown and related studies → Original source
42 participants completed the study (NR = 22, placebo = 20). 5 key findings →
Participants: 42 Evidence: high
Full summary, score breakdown and related studies → Original source
EVOKE (ClinicalTrials.gov NCT04777396) and EVOKE+ (NCT04777409) tested whether oral semaglutide, the GLP-1 diabetes/weight-loss drug, could slow early Alzheimer's disease progression in a combined 3,808 participants over up to 156 weeks. 4 key findings →
Design: phase-3-trial Participants: 3,808 Evidence: null result
Full summary, score breakdown and related studies → Original source
Individuals with cognitive profiles consistent with probable executive MCI were identified using simple assessments of global cognition, memory and executive functions in a community-dwelling older population. 2 key findings →
Design: randomized controlled trial Participants: 161 Evidence: high
Full summary, score breakdown and related studies → Original source
Of the 120 participants (mean age, 71.4 [SD, 8.6] years; 55% were female), 93 (77.5%) completed the trial. 1 key finding →
Design: phase-2-trial Participants: 120 Evidence: null result
Full summary, score breakdown and related studies → Original source Free full text
Curcumin exhibits neuroprotective activity in preclinical models of the four NDs analysed, acting on six interconnected mechanisms and the gut-brain axis. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
The PROMPPT trial will assess whether review by trained clinical pharmacists working in general practices can support safe opioid reduction without compromising pain management and quality of life. 2 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source
No benefits were demonstrated for secondary clinical end points. 3 key findings →
Design: phase-2-trial Participants: 327 Evidence: null result
Full summary, score breakdown and related studies → Original source Free full text
Donanemab, a monoclonal antibody targeting the insoluble form of β-amyloid found in plaques, significantly slows cognitive and functional decline of AD in participants with mild cognitive impairment (MCI) or mild AD-related dementia. 4 key findings →
Design: phase-3-trial Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
It was not possible to demonstrate significant differences on the co-primary clinical endpoints (ADAS-cog 11 and ADCS-ADL 23 ) at 52 weeks due to symptomatic activity in the control arm. 5 key findings →
Design: phase-3-trial Participants: 598 Evidence: null result
Full summary, score breakdown and related studies → Original source Free full text
Among 2711 decedents (mean [SD] age, 73.4 [14.4] years; range, 23 to 111 years; 1340 [49.4%] female), 531 (19.6%) met both thresholds, 270 (10.0%) the amyloid threshold only, 207 (7.6%) the tau threshold only, and 1703 (62.8%) neither. 3 key findings →
Design: cross-sectional Participants: 1,467 Evidence: moderate
Full summary, score breakdown and related studies → Original source
In this trial, $5 and $25 noncontingent monetary incentives included in mailed recruitment letters did not produce a detectable improvement in response among ADRD caregiving dyads. 4 key findings →
Design: randomized controlled trial Participants: 103 Evidence: high
Full summary, score breakdown and related studies → Original source
Older adults in senior living communities (SLCs) often face barriers to maintaining emotional well-being and family ties. 4 key findings →
Design: randomized controlled trial Participants: 90 Evidence: high
Full summary, score breakdown and related studies → Original source
We investigated brain, inflammation, cardiometabolic, and gut health changes associated with a six-month multidomain lifestyle intervention in Dutch older adults at risk for cognitive decline and dementia. 5 key findings →
Participants: 53 Evidence: high
Full summary, score breakdown and related studies → Original source
AD prevention must transcend the "geriatric disease" mindset. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Recent advances in blood-based biomarkers have transformed the early diagnosis of Alzheimer’s disease (AD), enabling the identification of biological risk at preclinical and presymptomatic stages in a noninvasive and accessible manner. 5 key findings →
Design: clinical trial Evidence: low
Full summary, score breakdown and related studies → Original source
Practice testing with detailed, corrective feedback is an effective intervention for targeting caregivers’ dementia-related knowledge. 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source
This provides the first evidence in older adults with cognitive concerns that higher step counts are associated with fewer depressive but more anxiety symptoms. 5 key findings →
Design: randomized controlled trial Participants: 629 Evidence: high
Full summary, score breakdown and related studies → Original source
Polygenic scores summarise genetic predisposition to a trait, but a population-level accuracy figure cannot tell a clinician whether a given prediction is reliable for the person in front of them. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
A 12-week HIIT+RT intervention was more effective than HIIT alone in increasing the thickness/volume signature in individuals with CAD, yet no differences were observed compared to UC and the interventions did not affect the GMMD signature. 5 key findings →
Design: randomized controlled trial Participants: 105 Evidence: high
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →